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http://www.biomedcentral.com/1471-2253/14/124RESEARCH ARTICLE Open AccessCirculating anti-inflammatory adipokines High
Molecular Weight Adiponectin and Zinc-α2-
glycoprotein (ZAG) are inhibited in early sepsis,
but increase with clinical recovery: a pilot study
Ingeborg D Welters1,2*, Chen Bing1, Cherlyn Ding1, Martin Leuwer3 and Alison M Hall1,2Abstract
Background: Adipose tissue has been identified as an endocrine organ secreting adipokines involved in metabolic
and inflammatory pathways. Adiponectin, an anti-inflammatory adipokine, is reduced in sepsis. High Molecular
Weight (HMW) adiponectin, the biologically most relevant molecule, has been investigated very little in human
sepsis. Zinc-alpha2-glycoprotein (ZAG) is a novel adipokine and its expression in adipose tissue is positively
correlated with adiponectin expression. It is not yet known whether ZAG has a role in sepsis. In this study we
assessed levels of HMW adiponectin and ZAG during different stages of sepsis.
Methods: A prospective observational pilot study was carried out on 21 septic patients. Serum samples were taken
on day 1 and 2 post ICU admission and on day of discharge. Samples were analysed for total and HMW
adiponectin, HMW/total adiponectin ratio, and ZAG. Results were correlated with clinical and metabolic data.
Results: There were no differences in total adiponectin, HMW adiponectin and ZAG plasma concentrations
between day 1 (admission) and day 2 of the sepsis episode. Compared to admission, a significant increase in total
and HMW adiponectin and ZAG was observed on the day of discharge when clinical improvement had been
achieved. There was also an increase in the HMW/total adiponectin ratio at that time.
Conclusions: Our data demonstrate an increase in both HMW adiponectin and total adiponectin in patients who
had clinically recovered from sepsis. The increase in HMW/total adiponectin ratio with improvement of the clinical
condition suggests that HMW adiponectin may have a greater role in the inflammatory process and insulin
resistance seen in sepsis. In this pilot study, we have also demonstrated a significant increase in ZAG in critically ill
patients temporally related to recovery from sepsis.
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In the last 15 years, white adipose tissue (WAT) has
been identified as a sophisticated endocrine organ se-
creting adipokines with a myriad of different functions
including involvement in metabolic, inflammatory and
proliferative pathways [1]. Whilst most adipokines pos-
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unless otherwise stated.Zinc-α2-glycoprotein (ZAG) have been proposed as
potential anti-inflammatory mediators released from
WAT [1,2].
ZAG, a soluble protein first isolated from human
plasma, has originally been regarded a cancer marker,
since its levels are elevated in patients with prostate and
cervical cancer [2]. However, ZAG is also expressed in
WAT and secreted by adipocytes [3,4]. Expression and
secretion of ZAG by human adipocytes is suppressed by
macrophage-derived factors and TNF-α, paralleling re-
lease patterns for adiponectin [5]. Gene expression of
adiponectin and ZAG in WAT is down-regulated in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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human adipocytes [6] and increases lipid loss in cachexia
by stimulating lipolysis [7]. Cachexia is common during
and after critical illness, suggesting a potential role for
ZAG. However, changes in ZAG concentrations in sepsis
have not been studied to date.
Adiponectin is now considered the major anti-
inflammatory adipokine produced by WAT [8]. Its
numerous actions include reduction of the phagocytic
activity of macrophages and inhibition of the produc-
tion of inflammatory cytokines from macrophages and
adipose tissue [9-16]. Adipocytes release different olig-
omeric isoforms of adiponectin, including trimeric,
hexameric and the high molecular weight (HMW) olig-
omeric complex [17]. HMW adiponectin is postulated
as the more biologically active molecule, binding avidly
to its receptors, thus stimulating AMP activated protein
kinase [18-20].
We have previously demonstrated that total adiponec-
tin production is reduced in mice following treatment
with lipopolysaccharide, suggesting that adiponectin is
actively involved in the inflammatory response of WAT
[21]. Recent clinical studies have shown that circulating
concentrations of total adiponectin are low in the acute
phase of sepsis and increase with recovery [22]. To date
no clinical studies have investigated the role of HMW
adiponectin in relation to total adiponectin concentra-
tions in acute life-threatening infection.
We therefore aimed to investigate the serum concen-
trations of high molecular weight adiponectin and its
relation to total circulating adiponectin in septic pa-
tients. To evaluate whether further anti-inflammatory
adipokines undergo similar changes during acute phase
sepsis and clinical recovery we also determined serum
levels of ZAG.
Methods
A prospective observational study was carried out to de-
termine the plasma concentrations of total and HMW adi-
ponectin in septic patients. Ethical approval was received
from the Local Research and Ethics committee (Liverpool
Paediatric Research Ethics Committee 06/Q1502/7) and
from the NHS trust (no 3258) allowing witnessed assent
from relatives with patients being informed as soon as
practical to obtain retrospective consent.
Patient recruitment
21 patients (18–85 years) admitted to the Intensive Care
Unit (ICU) at the Royal Liverpool University Hospital
with sepsis or septic shock according to ACCP /SCCM
Consensus Conference guidelines were recruited into
the study [23].
Exclusion criteria were pregnancy/lactation, insuli-
noma, immunosuppression due to other causes thansepsis (post organ transplant, AIDS, ongoing chemother-
apy), and <18 years of age. Demographic, clinical and la-
boratory data were collected. Data relating to ongoing
therapies (inotrope and insulin requirements, feeding re-
gime, and daily glucose and lactate measurements) were
also collected. Serum samples were taken from each patient
on admission to ICU. Further serum samples were taken
on day 2 and on day of discharge. For patients who died,
only day 1 and day 2 samples were taken. Following centri-
fugation (10 minutes at 3000 rpm), serum was obtained, ali-
quoted and stored at −80 C until analysis.
Sample analysis
Total adiponectin ELISA
(R&D Systems DY1065): Samples were homogenized
in lysis buffer (sucrose 250 mM/HEPES 1 mM/EDTA
0.2 mM, pH 7.2). Capture antibody (2 μg/ml) was used to
coat a 96 well plate. Plates were blocked using 1% Bovine
Serum Albumin (BSA) in Phosphate-buffered Saline (PBS).
Samples and standards (diluted in 1% BSA in PBS) were
added to the plate and incubated. After washing, detection
antibody (concentration 2 μg/ml) was added to each well
and following incubation, Streptavadin-HRP (concentra-
tion 1/200) was added. Colour substrate solution (1:1 mix-
ture of Colour Reagent A (H2O2) and Colour Reagent B
(Tetramethylbenzidine, 1:1 dilution) was added and the re-
action stopped using stop solution (2NH2SO4). Optical
density was determined using a microplate reader at dual
wavelength 450 nm with a reference wavelength 570 nm.A
high standard of 4000 pg/ml was used with serial dilutions.
High molecular weight adiponectin
(ALPCO, Salem, USA): All measurements were performed
according to the manufacturer’s instructions. In brief, sam-
ples were pre-treated with Protease II and the remaining
HMW fraction was treated with sample pre-treatment buf-
fer. Protease I was combined with the sample and incu-
bated at 37 C. Immediately, sample pre-treatment buffer
was added, vortexed and diluted. 50 μl of each standard di-
luted pre-treated sample was added to the appropriate
wells and incubated at room temperature. Following wash-
ing, biotin labelled monoclonal antibody was added to each
well and incubated. Following a second wash, enzyme la-
belled streptavidin was added to each well and incubated.
Subsequently, substrate solution was added to each well
and following incubation, the reaction was terminated
using stop reagent. The absorbance of each well was mea-
sured using a microplate reader set to 492 nm, with a refer-
ence wavelength of 600–700 nm.
Zinc-α2-glycoprotein (ZAG)
(BioVendor, Laborartorni Medicina a.s, Czech Republic):
All measurements were performed according to the
manufacturer’s instructions. In brief, 100 μl of diluted
Table 1 Biometric and clinical data on admission, day 1
and day of discharge
n Median Range Mean ± SD 95% CI
Age (years) 21 63 [55; 71] 62.2 ± 14.1 [55.84; 68.64]
APACHE II 21 20 [18; 24] 20.8 ± 6.5 [17.86; 23.76]
Temp (°C) 19 37.1 [36.95; 38.15] 37.2 ± 1.4 [36.57; 37.91]
FiO2 21 0.6 [0.5; 0.8] 0.6 ± 0.2 [0.53; 0.75]
Height (cm) 21 167 [162; 176] 167.9 ± 9.6 [163.5; 172.29]
Weight (kg) 21 84.4 [71; 93] 81.5 ± 16.3 [74.08; 88.94]
BMI (kg.m2) 21 30 [24; 32.08] 29.1 ± 6.6 [26.1; 32.13]
LOS (days) 21 7 [3; 15] 9.3 ± 8.4 [5.46; 13.12]
Biometric data for all patients including age, severity of illness scoring
(APACHE II), height, weight and length of stay (LOS) in the ICU. Parameters are
displayed as median, range (IQR), mean ± standard deviation (SD) and 95%
confidence intervals (CI) of means (APACHE: acute physiology and chronic
health evaluation, BMI: Body mass index).
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http://www.biomedcentral.com/1471-2253/14/124standards, quality controls, dilution buffer and diluted
samples, were pipetted into a 96-microtitre plate in du-
plicate. The plate was incubated at room temperature
for 1 hour after three washes, 100 μl of Conjugate Solu-
tion was pipetted into each well and incubated at roomTable 2 Laboratory results on admission, day 1 and day of di
Admission n Median
WCC (x10/L) 21 23
CRP (mg/L) 18 198
Hb (g/dL) 21 10.3
Creatinine (μmol/L) 21 114
Urea (mmol/L) 21 9.2
Bilirubin (μmol/L) 20 15.0
Glucose (mmol/L) 21 6.65
Day 2
WCC (x10/L) 21 22.2
CRP (mg/L) 9 234.0
Hb (g/dL) 21 9.5
Creatinine (μmol/L) 21 126.0
Urea (mmol/L) 21 10.1
Bilirubin (μmol/L) 21 15.0
Glucose (mmol/L) 21 7.3
Day of Discharge
WCC (x10/L) 18 14.9
CRP (mg/L) 6 66.5
Hb (g/dL) 18 9.3
Creatinine (μmol/L) 18 54.5
Urea (mmol/L) 18 7.6
Bilirubin (μmol/L) 18 9.5
Glucose (mmol/L) 18 6.3
Laboratory data obtained on admission to Intensive Care, on day 2 and on day of d
Hb: Haemoglobin. Parameters are displayed as median, range (IQR), mean ± standar
routinely measured during Intensive Care stay.temperature for a further 1 hour. After three washes,
100 μl of substrate solution was added into each well
and incubated for 10 minutes at room temperature. Re-
actions were stopped using 100 μl of Stop Solution and
the absorbance of each well was determined using a mi-
croplate reader set to 450 nm with reference wavelength
of 630 nm.
Statistical analysis
Descriptive data are presented as mean and standard de-
viation or as median and interquartile range as indicated.
Categorical parameters are given in cross tables. For
graphic representation boxplots were used. All data were
examined for normal distribution using normal Q-Q
plots and the Shapiro-Wilk test. Since the majority of
data were not normally distributed the nonparametric
Mann–Whitney U-Test was used for all analyses com-
paring two groups. The Chi-squared test was used to
determine any difference in categorical variables. The
non-parametric Wilcoxon test for paired data was used
to evaluate changes in time course. Correlations between
ZAG and adiponectin changes were assessed byscharge
Range Mean ± SD 95% CI
[11.7; 31.9] 21.7 ± 12.3 [16.1; 27.3]
[150.3; 240.5] 198.6 ± 22.2 [152.8; 244.5]
[8.5; 11.2] 10.2 ± 2.2 [9.2; 11.18]
[76; 183] 153.0 ± 123.2 [96.9; 209.0]
[7.4; 13.1] 11.4 ± 6.4 [8.5; 14.3]
[8.0; 34.8] 28.7 ± 30.2 [14.6; 42.9]
[5.86; 8.3] 7.3 ± 2.0 [6.4; 8.2]
[5.1; 36.6] 22.2 ± 10.3 [17.5; 26.9]
[107.0; 338.0] 236.1 ± 63.5 [284.9; 237.6]
[7.8; 13.5] 9.9 ± 1.7 [9.1; 10.6]
[35.0; 425] 137.0 ± 89.5 [177.8; 127.1]
[3.4; 33] 11.6 ± 6.2 [8.8; 14.4]
[3.0; 103.0] 28.8 ± 33.2 [13.6; 43.9]
[3.7; 10.7] 7.3 ± 1.5 [6.6; 8.0]
[8.6; 30.5] 16.8 ± 7.3 [13.3; 20.3]
[36.0; 199.0] 97.8 ± 67.1 [27.4; 168.3]
[8.0; 10.6] 9.1 ± 0.7 [8.7; 9.6]
[24.0; 285] 89.7 ± 71.5 [54.1; 125.2]
[2.7; 24.1] 9.2 ± 5.5 [6.5; 12.0]
[4.0; 430.0] 54.6 ± 110.8 [−0.5; 109.6]
[4.7; 9.7] 6.5 ± 1.3 [5.8; 7.1]
ischarge from Intensive Care. WCC: white cell count, CRP: C-Reactive protein,
d deviation (SD) and 95% confidence intervals (CI) of means. CRP is not
Figure 1 Total Plasma Adiponectin in on day 1, 2 and discharge. Serum concentrations of total adiponectin in septic patients. Figure
shows median and interquartile range (grey box). Comparisons were made between Day 1 and Day 2 and between Day 1 and Day of Discharge.
P values before Bonferroni correction are given in the graph. Corrected p value for Day 2 versus Day of Discharge is <0.02.
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cient as indicated.
Results are displayed as median and interquartile range
unless stated otherwise. Adjustments for multiple testing
were performed using Bonferroni’s procedure as indi-
cated. All statistics were performed with R version 2.8.0.
p < 0.05 was considered significant.Figure 2 High molecular weight Plasma Adiponectin on day 1, 2 and
adiponectin. Figure shows median and interquartile range (grey box). Compa
Day of Discharge. P values before Bonferroni correction are given in the graphResults
Biometric, clinical and laboratory data
Twenty-one patients with severe sepsis were recruited
into the study. Eight patients presented with abdominal
sepsis, 9 patients with chest sepsis, 1 patient with necro-
tising fasciitis, 2 patients with osteomyelitis and 1 pa-
tient with urinary sepsis. For 10 patients follow-up blooddischarge. Serum concentrations of High molecular weight (HMW)
risons were made between Day 1 and Day 2 and between Day 1 and
. Corrected p value for Day 2 versus Day of Discharge is <0.002.
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were discharged on day 2 and in 3 patients follow-up
blood samples for adipokine determination could not be
obtained). 10 patients were female and 11 were male.
Baseline clinical, laboratory and metabolic data are
shown in Tables 1 and 2. Median age was 63 years (55–71
years) with a median APACHE II score of 20. Clinically,
patients were not universally pyrexial but were tachy-
cardic and tachypneoic, all requiring more than 50%
supplemental oxygen. None of the patients required
blood products. Biochemical and haematological markers
(White cell count and C-Reactive Protein (CRP)) were ele-
vated and most had a degree of renal impairment. 9 of
the 21 patients had to be started on renal replacement
therapy for acute kidney injury. There was a positive
correlation of total adiponectin and severity of illness
scores (Day 1: r = 0.50, p < 0.01, Day 2: r = 0.42,
p < 0.01, Day of discharge 0.35, p < 0.05) as determined
by Spearman’s correlation coefficient. There was no sig-
nificant correlation between HMW adiponectin and
APACHE II score. No significant differences in total
and HMW adiponectin or ZAG were observed between
patients who survived and those who died. There were
also no differences in biometric data (age, gender, BMI)
and severity of disease (APACHE II).
On the day of admission 6 of 21 patients required
intravenous insulin infusion to maintain blood glucose
levels between 3.5 and 8 mmol/L. There was no signifi-
cant correlation with average amount of insulin requiredFigure 3 Ratio of HMW: Total plasma Adiponectin in all patients o
range (grey box). Comparisons were made between Day 1 and Day 2
paired data was used. P values before Bonferroni correction are given
is 0.02.per hour and weight, total and HMW adiponectin levels,
or ZAG levels at any time point.
Total Adiponectin and HMW adiponectin concentrations
Total adiponectin as well as HMW adiponectin concen-
trations were lower during the first two days of the sep-
tic episode. A significant increase in total and HMW
adiponectin was observed from day 1 (admission) to day
of discharge when the clinical condition had improved
enough to allow discharge from ICU (3.78 [2.86;4.25] vs
4.96 [4.41;8.16] μg/ml (p < 0.01) and 2.5 [1.7;3.5] vs 3.8
[2.45;7.8] μg/ml respectively (p < 0.01), Figures 1 and 2).
There were no differences in total and HMW adiponec-
tin concentrations between day one and two of the sep-
sis episode (p = 0.73 and p = 0.46 respectively).
The HMW/total adiponectin ratio increased during the
observation period (Figure 3). This indicates that forma-
tion of HMW adiponectin is suppressed more efficiently
in acute sepsis than production of other circulating forms
of adiponectin. Total adiponectin plasma concentrations
at day 1 correlated with APACHE II values as a marker of
severity of disease, while HMW adiponectin levels corre-
lated with CRP concentrations as a marker of the severity
of the inflammatory response (Table 3).
HMW adiponectin levels at discharge were higher in
women than men (7.7 [3.25; 8.1] vs 2.85 [2.05; 3.625]
μg/ml, p = 0.036) which is consistent with the current
literature [24-27]. During the acute illness, both sexes
had similar HMW and total adiponectin concentrationsn day 1, 2 and discharge. Figure shows median and interquartile
and between Day 2 and Day of Discharge. Wilcoxon test for
in the graph. Corrected p value for Day 2 versus Day of Discharge
Table 3 Correlation between adiponectin, ZAG and severity of disease
APACHE II (n = 21) WCC (n = 21) CRP (n = 18)
HMW adiponectin day 1 0.371 (p = 0.098) 0.049 (p = 0.833) −0.565 (p = 0.014)
HMW adiponectin day 2 0.415 (p = 0.062) 0.173 (p = 0.453) −0.370 (p = 0.131)
Total adiponectin day 1 0.503 (p = 0.020) 0.042 (p = 0.858) −0.126 (p = 0.618)
Total adiponectin day 2 0.415 (p = 0.061) 0.084 (p = 0.716) −0.229 (p = 0.360)
HMW/total Adiponectin day 1 −0.142 (p = 0.539) −0.064 (p = 0.784) −0.447 (p = 0.063)
HMW/total Adiponectin day 2 −0.267 (p = 0.242) −0.023 (p = 0.920) −0.272 (p = 0.276)
ZAG day 1 0.237 (p = 0.301) 0.362 (p = 0.106) 0.371 (p = 0.130)
ZAG day 2 0.249 (p = 0.277) 0.371 (p = 0.098) 0.463 (p = 0.053)
Correlations between adiponectin and ZAG concentrations respectively and severity of disease and inflammatory response. Spearman rank test was used for
all correlations.
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p = 0.97). However, on recovery the concentration of
HMW in women had increased significantly (p = 0.02)
whereas in men it remained unchanged (p = 0.7).
Serum concentrations of ZAG and correlation with
adiponectin levels
Similar to total and HMW adiponectin concentrations,
levels of circulating ZAG were significantly lower at day 1
and day 2 of sepsis and increased significantly with an im-
proved clinical condition at discharge from Intensive Care
(Figure 4). In patients surviving to discharge (n = 11), a
significant correlation between the change in adiponectin
(total and HMW) and the change in ZAG serumFigure 4 Plasma ZAG in all patients on day 1, 2 and discharge. ZAG se
interquartile range (grey box). Wilcoxon test for paired data was used. Com
and Day of Discharge. P values before Bonferroni correction are given in th
is 0.0036.concentrations was observed (Figure 5). No gender differ-
ences were observed for ZAG concentrations on admis-
sion or at discharge.
Comparison between obese and non-obese patients
To evaluate the influence of obesity on severity of dis-
ease and degree of systemic inflammation, comparisons
were made between patients presenting with a Body
Mass Index (BMI) above and below 30 (Table 4). There
were no differences ion APACHE II scores, age, and rou-
tine laboratory results on admission. No differences were
found in serum concentrations of HMW and total adi-
ponectin on admission. Also, ZAG serum concentrations
were comparable in both groups. There were also norum concentrations as measured by ELISA. Figure shows median and
parisons were made between Day 1 and Day 2 and between Day 2
e graph. Corrected p value for Day 2 versus Day of Discharge
Figure 5 Correlation between change of HMW adiponectin, total adiponectin and ZAG. Cutting point between imaginary vertical and
horizontal lines show Correlation between change of HMW adiponectin, total adiponectin and ZAG in graphic form on the left and Spearman’s
and Pearson’s correlation coefficient on the right cutting point.
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ZAG levels between obese and non-obese patients on
day 2 and at the time of Intensive Care discharge.Discussion
Adiponectin has been shown to be down-regulated in ex-
perimental endotoxaemia. HMW adiponectin, however, has
been investigated less, despite some evidence that it is the
more active of the different multimers of adiponectin
[18,27]. Our data demonstrate that both HMW adiponectin
and total adiponectin concentrations significantly increased
between day 1 and day of discharge. This increase in adipo-
nectin was accompanied by a significant clinical improve-
ment in condition, such that intensive care was no longer
required. Our results support findings of previous studies
demonstrating that total adiponectin increases not only until
recovery to discharge, but also up to 8 months after critical
illness [28,29]. Increasing adiponectin concentrations during
recovery may reflect resolution of the pro-inflammatoryprocess or a metabolic change indicating a shift towards an
anti-inflammatory situation with improved insulin sensitivity.
Emerging literature has demonstrated a greater correl-
ation between markers of insulin resistance and HMW
adiponectin rather than the total adiponectin concentra-
tion in chronic disease [18,30], leading to the concept of
HMW/total adiponectin ratio as a more sensitive assess-
ment of glucose metabolism. Even without changes in
total adiponectin, increases in the ratio reflecting a rise in
the HMW adiponectin multimer, confer favourable effects
on insulin sensitivity and other metabolic parameters.
Therefore, the HMW adiponectin/total adiponectin ratio
has been proposed as a useful monitoring tool to assess
response drug treatment in Type II DM. In our study the
HMW/total adiponectin ratio increased during the obser-
vation period, suggesting that the contribution from
HMW adiponectin is greater in patients having recovered
from sepsis than in patients during their acute stage of
sepsis. Patients recruited into this study are a representa-
tive sample of patients with sepsis, displaying comparable
Table 4 Comparison between obese (BMI > 30) and non-obese (BMI < 30) patients
BMI < 30 BMI > = 30
n Mean CI Median Range n Mean CI Median Range P value
Age (Years) 10 63.2 ± 18.1 [50.3; 76.3] 67 [53.0; 73.3] 11 61.4 9 ± 9. [54.7; 68.0] 61 [57; 67] p = 0.622
APACHE 10 19.1 ± 5.6 [15.1; 23.1] 20 [15.25; 22.0] 11 22.4 ± 7.1 [17.6; 27.1] 20 [18.5; 28] p = 0.458
BMI 10 23.4 ± 1.5 [22.3; 24.5] 23.85 [22.3; 24.2] 11 34.3 ± 4.8 [31.7; 37.6] 32.1 [30.95; 36.6] p < 0.001
WCC (x10/L) 10 20.5 ± 12.9 [11.2; 29.8] 24.85 [8.8; 30.9] 11 22.8 ± 12.1 [14.7; 31.0] 22.8 [16.25; 29.5] p = 0.860
CRP (mg/L) 8 201.6 ± 95.2. [122.1; 281.2] 214.5 [174.5; 251.8] 10 196.2 ± 94.9 [128.3; 264.1] 186 [150.25; 199] p = 0.351
Hb (g/dL) 10 10.8 ± 2.54 [9.0; 12.6] 10.5 [8.6; 11.8] 11 9.7 ± 1.7 [8.5; 10.8 ] 10.0 [8.55; 11.2] p = 0.503
Creatinine (μmol/L) 10 149.0 ± 99.7 [77.7; 220.3] 120 [82.0; 198.8] 11 156.6 ± 146.2 [58.3; 254.8] 106 [72.5; 136] p = 0.833
Urea (mmol/L) 10 11.6 ± 6.8 [6.7; 16.5] 10.5 [7.4; 12.9] 11 11.3 ± 6.3 [7.1; 15.5] 8.7 [7.6; 12.7] p = 0.751
Bilirubin (μmol/L) 9 19.3 ± 14.5 [8.2; 30.5] 14 [8.0; 25] 11 36.4 ± 37.7 [11.0; 61.7] 16 [7.5; 70.5] p = 0.761
Glucose (mmol/L) 10 5.8 ± 1.8 [4.5; 7.1] 5.65 [4.4; 6.8] 11 7.4 ± 2.5 [5.7; 9.0] 7 [5.75; 8.4] p = 0.121
HMW-Adipo (μg/ml) 10 2.2 ± 1.3 [1.2; 3.1] 1.75 [1.3; 2.7] 11 2.9 ± 1.0 [2.3; 3.6] 2.9 [2.2; 3.7] p = 0.130
Total Adipo (μg/ml) 10 3.6 ± 1.5 [2.5; 4.7] 3.29 [2.8; 4.2] 11 4.1 ± 1.8 [2.9; 5.3] 3.8 [3.08; 4.3] p = 0.573
ZAG (ng/ml) 10 29473 [22888; 36058] 26490 [23563; 32385] 11 31859.09 [26585; 37133] 30480 [27725; 36223] p = 0.439
Laboratory and biometric data obtained on admission to Intensive Care comparing patients with body mass index <30 and those with body mass index >30. BMI : Body Mass Index, WCC: white cell count, CRP:
C-Reactive protein, Hb: Haemoglobin. HMW Adipo: High Molecular Weight Adiponectin, Total Adipo: Total Adiponectin, ZAG: Zinc-α2-glycoprotein. Parameters are displayed as median, range (IQR), mean ± standard
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mean BMI of 29 reflects the national average (28.2) in the
UK, hence a representative patient sample was investi-
gated. The correlation between BMI and adiponectin
levels has been clearly established in large epidemiological
studies. In our study, sample sizes of 10 and 11 patients
do not allow conclusions about the impact of body fat on
adiponectin levels. The fact that we saw a significant in-
crease in adiponectin concentrations along with clinical
recovery, suggests that a massive systemic activation of
the immune system as part of the septic response may
have a greater impact on serum adiponectin than the
obesity status of the patients. Despite the severity of dis-
ease (Median APACHE score 20), mean admission glu-
cose levels were below 8 mmol/L with no significant
differences between the groups. As part of standard care
tight glucose control was achieved by continuous intra-
venous insulin administration, which together with the
methodological difficulties to assess insulin sensitivity
in critical illness prevents conclusions about insulin and
glucose metabolism in relation to adiponectin changes
in our study.
Although the results of this small study require confirm-
ation in a larger patient cohort, a biological role of different
adiponectin isoforms in sepsis is likely. The therapeutic po-
tential to modify adiponectin in order to improve recovery
and insulin-sensitivity during acute sepsis will have to be
explored in future studies. HMW adiponectin concentra-
tions were higher in females than in males at discharge
from intensive care which correlates to previous studies
[18,25-27], suggesting a differing regulation of adiponectin
between the sexes. This is the first time this has been dem-
onstrated in sepsis. These gender differences were limited
to adiponectin concentrations with ZAG levels being simi-
lar in both genders on admission as well as at discharge.
These findings even in a small patient population indicate
that gender differences need to be taken into consideration
and that the impact of adiponectin increases on outcome
and recovery from critical illness may differ between fe-
male and male patients.
In this study we show for the first time that circulating
levels of ZAG, an adipokine known to induce cachexia
in cancer patients are decreased in acute sepsis and rise
during clinical recovery. Furthermore, the course of cir-
culating ZAG concentrations mimics the pattern found
for total and HMW adiponectin. We have previously
demonstrated that adiponectin production is down-
regulated in WAT of mice as part of the inflammatory
response to Lipopolysaccharide [21]. These results were
confirmed and extended in a recent study demonstrating
decreased adiponectin concentrations in mice challenged
with LPS [34]. Interestingly, Pini et al. could demon-
strate that obese mice showed a greater weight loss
seven days after LPS challenge than lean mice.The results of this single-centre pilot study will have
to be confirmed; however, a biological role of different
adiponectin isoforms in sepsis appears plausible. In par-
ticular, the observed increase of ZAG concentrations
during recovery from critical illness should be investi-
gated in a larger patient cohort with an emphasis on a
potential correlation with functional data about muscle
strength, weight loss and glucose tolerance. The lack of
data from patients who did not survive represents a fur-
ther limitation. Whilst these samples may have given
valuable data in patients in whom the inflammatory
process did not resolve, for obvious ethical reasons we
could not obtain these samples. Due to the small sample
size we could not exclude gender, Body Mass Index, age
and different aetiologies of sepsis as potential con-
founders. We did not find significant differences in ad-
mission blood results and adipokine levels between
survivors and non-survivors. However, the sample size
presented here is too small to allow for conclusions
about the role of adiponectin in the outcome of sepsis.
Conclusions
In conclusion, we have demonstrated a significant in-
crease in total and HMW adiponectin and ZAG tempor-
ally related to clinical recovery from sepsis. These results
encourage further studies investigating the relationship
between different adiponectin isoforms and ZAG to ex-
plore the therapeutic potential of modulating either of
these proteins in sepsis.
Key messages
 HMW and total adiponectin and ZAG levels are
lower on day of admission to ICU compared to day
of discharge
 HMW and total adiponectin and ZAG levels
significantly increase with clinical recovery from sepsis
 In patients surviving to discharge, there is a
significant correlation between change in ZAG and
adiponectin concentration
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